Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients.
Shuling WangYuqin ChenWeidong LiChunfang HaoLi ZhangWeipeng ZhaoYehui ShiZhongsheng TongPublished in: Breast cancer (Dove Medical Press) (2024)
Our study showed that patients with advanced breast cancer had a high level of sHER2 at recurrence, regardless of whether they are tHER2 positive or negative. Dynamic detection of sHER2 can help predict therapeutic efficacy and prognosis, regardless of whether tHER-2 is positive or negative.
Keyphrases